Back to discover
Drug

Abciximab

In clinical development
Emerging researchLate-stage development

Also known as Reopro, c7E3.

RxNorm83929UNIIX85G7936GV
2
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Stroke Prevention With Abciximab in Carotid Endarterectomy

Clinical trial2015-12-18Withdrawn · ClinicalTrials.gov

A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function

Clinical trial2014-06-01Primary completion · ClinicalTrials.gov

Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction

Clinical trial2012-11-27Results posted · ClinicalTrials.gov

IntraCoronary Abciximab With the ClearWay Catheter To Improve Outcomes With Lysis

Clinical trial2011-06-01Terminated · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Abciximab
Aliases & brands
Reoproc7E3
RxNorm CUI
83929
UNII
X85G7936GV

Clinical trials

31 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
31
registered trials across all phases
LATEST COMPLETION 2013
26
Late-stage (III+)
17
Completed
14
Discontinued
PHASE DISTRIBUTIONn = 31
Phase 1 / 21Phase 24Phase 2 / 31Phase 310Phase 412Phase N / A3

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials